Skip to content

Donanemab and Lecanemab rejected for the NHS

Two innovative Alzheimer’s drugs, Donanemab and Lecanemab, have been rejected by the NHS due to their exorbitant cost and limited impact. These are the first treatments to slow the disease, potentially extending

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

2025 Government Spending Review

The UK Government's Spending Review, announced on June 11, 2025, by Chancellor Rachel Reeves, outlined spending and investment plans through 2029 - 30, addressing key public

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Secondary dementia problems

Alzheimer’s disease is often seen as a brain problem, but new evidence shows it can affect other body parts too. Scientists at Baylor College of Medicine

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here